A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients

Cancer Investigation

Volumn 25, Issue 5, 2007, Pages 285-293

  Faries, Mark B ^a   Gupta, Rishab K ^a   Ye, Xing ^a   Lee, Christopher ^a   Yee, Reynold ^a   Leopoldo, Zacharias ^a   Essner, Richard ^a   Foshag, Leland J ^a   Elashoff, David ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Immune complex; Melanoma; MIA; SI00B; TA90; Tumor marker

Indexed keywords

BCG VACCINE; CANCER VACCINE; CANVAXIN; MELANOMA INHIBITING ACTIVITY PROTEIN; PROTEIN; PROTEIN S100B; TA90 IMMUNE COMPLEX; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ANTIGENS, NEOPLASM; CANCER VACCINES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROGNOSIS; RECURRENCE; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547520135     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701208634     Document Type: Article

References (35)

1. Balch, C.; Buzaid, A.; Soong, S.; Atkins, M.; Cascinelli, N.; et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001, 19, 3635-3648.
2. Hsueh, E.; Essner, R.; Foshag, L.; Ollila, D.; Gammon, G.; O'Day, S.; Boasberg, P.; Stern, S.; Ye, X.; Morton, D. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 2002, 20, 4549-4554.
3. Balch, C.; Soong, S.; Atkins, M.; Buzaid, A.; Cascinelli, N.; et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J. Clin. 2004, 54, 131-149.
4. Rebmann, V.; Ugurel, S.; Tilgen, W.; Reinhold, U.; Grosse-Wilde, H. Souble HLA-DR is a potent predicitive indicator of disease progression in serum from early-stage melanoma patients. Int. J. Cancer 2002, 100, 580-585.
5. Banfalvi, T.; Gilde, K.; Boldizsar, M.; Kremmer, T. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma. Neoplasma. 2002, 49, 121-125.
6. Gogas, H.; Kefala, G.; Bafaloukos, D.; Frangia, K.; Polyzos, A.; et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer 2002, 87, 181-186.
7. Wakamatsu, K.; Kageshita, T.; Furue, M.; Hatta, N.; Kiyohara, Y.; et al. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience. Melanoma Res. 2002, 12, 245-253.
8. Stoitchkov, K.; Letellier, S.; Garnier, J.; Bousquet, B.; Tsankov, N.; et al. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B. Melanoma Res. 2002, 12, 255-262.
9. Vuoristo, M.; Kellokumpu-Lehtinen, P.; Laine, S.; Parvinen, L.; Hahka-Kemppinen, M.; et al. The value of serum S-100B and interleukins as tumour markers in advanced melanoma. Melanoma Res. 2000, 10, 237-241.
10. Dutcher J. The prognostic role of detecting circulating melanoma cells in the blood. J. Clin. Oncol. 2003, 21, 757-759.
11. Wascher, R.; Morton, D.; Kuo, C.; Elashoff, R.; Wang, H.; et al. Molecular tumor markers in the blood: Early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J. Clin. Oncol. 2003, 21, 2558-2563.
12. Gupta, R.; Morton, D. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer. J. Clin. Lab. Analysis. 1992, 6, 329-336.
13. Gupta, R.; Morton, D. Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J. Natl. Cancer Inst. 1983, 70, 993.
14. Hsueh, E.; Gupta, R.; Qi, K.; Yee, R.; Leopoldo, Z.; et al. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J. Sci. Am. 1997, 3, 364-370.
15. Euhus, D.; Gupta, R.; Morton, D. Characterization of a 90-100 kDa Tumor-associated antigen in the sera of melanoma patients. Int. J. Cancer. 1990, 45, 1065-1070.
16. Tsioulias, G.; Gupta, R.; Tisman, G.; Hsueh, E.; Essner, R.; et al. Serum TA90 antigen-antibody complex as a surrogate marker of the efficacy of a polyvalent allogeneic whole-cell vaccine (Cancer-Vax) in melanoma. Ann. Surg. Oncol. 2001, 8, 198-203.
17. Bosserhoff, A.; Kaufmann, M.; Kaluza, B.; Bartke, I.; Zirngibl, H.; et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997, 57, 3149-3153.
18. Guba, M.; Bosserhoff, A.; Steinbauer, M.; Abels, C.; Anthuber, M.; et al. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel3 melanoma cells in vivo. Br. J. Cancer. 2000, 83, 1216-1222.
19. Bosserhoff, A.; Buettner, R. Expression, function and clinical relevance of MIA (melanoma inhibitory activity.). Histol Histopathol. 2002, 17, 289-300.
20. Meral, R.; Duranyildiz, D.; Tas, F.; Camlica, H.; Yasasever, V.; et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma., Melanoma Res. 2001, 11, 627-632.
21. Dreau, D.; Bosserhoff, A.; White, R.; Buettner, R.; Holder, W. Melanoma-inhibiting activity protein concentrations in blood of melanoma patients treated with immunotherapy. Oncol. Res. 1999, 11, 55-61.
22. Faries, M.; Gupta, R.; Ye, X.; Hsueh, E.; Morton, D. Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer Stage III melanoma. Ann. Surg. Oncol. 2004, 11, 85-93.
23. Cochran, A.; Lu, H.; Li, P.; Saxton, R.; Wen, D. S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res. 1993, 3, 325-330.
24. Acland, K.; Evans, A.; Abraha, H.; Healy, C.; Roblin, P.; et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br. J. Dermatol. 2002, 146, 832-835.
25. Reinhardt, M.; Kensy, J.; Frohmann, J.; Willkomm, P.; Reinhold, U.; et al. Value of tumor marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin. 2002, 41, 143-147.
26. Deichmann, M.; Benner, A.; Bock, M.; Jackel, A.; Uhl, K.; et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J. Clin. Oncol. 1999, 17, 1891-1896.
27. Djukanovic, D.; Hofmann, U.; Sucker, A.; Rittgen, W.; Schadendorf, D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res. 2000, 20, 2203-2207.
28. Juergensen, A.; Holzapfel, U.; Hein, R.; Stolz, W.; Buettner, R. et al. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol. 2001, 22, 54-58.
29. Krahn, G.; Kaskel, P.; Sander, S.; Waizenhofer, P.; Wortmann, S.; et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastasis compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001, 21, 1311-1316.
30. Schmitz, C.; Brenner, W.; Henze, E.; Christophers, E.; Hauschild, A. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res. 2000, 20, 5059-5063.
31. Garbe, C.; Leiter, U.; Ellwanger, U.; Blaheta, H.; Meier, F.; et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibiting activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 2003, 97, 1737-1745.
32. Gupta, R.; Theofilopoulos, A.; Dixon, F.; Morton, D. Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma. Cancer Immunol. Immunother. 1979, 6, 211-221.
33. Hoon, D.; Bostick, P.; Kuo, C.; Okamoto, T.; Wang, H.; et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000, 60, 2253-2257.
34. Dunn, G.; Bruce, A.; Ikeda, H.; Old, L.; Schreiber, R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998.
35. Mackie, R.; Reid, R.; Junor, B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 2003, 34, 567-568.